Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remnant Ablation Therapy in Low-risk Differentiated Thyroid Cancer
NCT02418247Phase 3Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2013
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iodine-131 in differentiated thyroid cancer (DTC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
iodine-131
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT02418247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418247.